| A decade of direct-to-consumer advertising of prescription drugs JM Donohue, M Cevasco, MB Rosenthal New England Journal of Medicine 357 (7), 673-681, 2007 | 724 | 2007 |
| Promotion of prescription drugs to consumers MB Rosenthal, ER Berndt, JM Donohue, RG Frank, AM Epstein New England Journal of Medicine 346 (7), 498-505, 2002 | 684 | 2002 |
| Reducing the societal burden of depression: a review of economic costs, quality of care and effects of treatment JM Donohue, HA Pincus Pharmacoeconomics 25, 7-24, 2007 | 338 | 2007 |
| Demand effects of recent changes in prescription drug promotion MB Rosenthal, ER Berndt, JM Donohue, AM Epstein, RG Frank Forum for Health Economics & Policy 6 (1), 2003 | 290 | 2003 |
| COVID-19 and school closures JM Donohue, E Miller Jama 324 (9), 845-847, 2020 | 271 | 2020 |
| A history of drug advertising: the evolving roles of consumers and consumer protection J Donohue The Milbank Quarterly 84 (4), 659-699, 2006 | 254 | 2006 |
| The impact of national health care reform on adults with severe mental disorders RL Garfield, SH Zuvekas, JR Lave, JM Donohue American Journal of Psychiatry 168 (5), 486-494, 2011 | 214 | 2011 |
| Evaluation of machine-learning algorithms for predicting opioid overdose risk among medicare beneficiaries with opioid prescriptions WH Lo-Ciganic, JL Huang, HH Zhang, JC Weiss, Y Wu, CK Kwoh, ... JAMA network open 2 (3), e190968-e190968, 2019 | 193 | 2019 |
| Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression JM Donohue, ER Berndt, M Rosenthal, AM Epstein, RG Frank Medical care 42 (12), 1176-1185, 2004 | 192 | 2004 |
| Effects of direct-to-consumer advertising on medication choice: The case of antidepressants JM Donohue, ER Berndt Journal of Public Policy & Marketing 23 (2), 115-127, 2004 | 174 | 2004 |
| Hepatitis C disease burden in the United States in the era of oral direct‐acting antivirals J Chhatwal, X Wang, T Ayer, M Kabiri, RT Chung, C Hur, JM Donohue, ... Hepatology 64 (5), 1442-1450, 2016 | 171 | 2016 |
| The effect of Medicare Part D on drug and medical spending Y Zhang, JM Donohue, JR Lave, G O'Donnell, JP Newhouse New England Journal of Medicine 361 (1), 52-61, 2009 | 166 | 2009 |
| Prevalence and correlates of self-reported medication non-adherence among older adults with coronary heart disease, diabetes mellitus, and/or hypertension ZA Marcum, Y Zheng, S Perera, E Strotmeyer, AB Newman, ... Research in Social and Administrative Pharmacy 9 (6), 817-827, 2013 | 148 | 2013 |
| Whom do older adults trust most to provide information about prescription drugs? JM Donohue, HA Huskamp, IB Wilson, J Weissman The American journal of geriatric pharmacotherapy 7 (2), 105-116, 2009 | 136 | 2009 |
| Health reform and the scope of benefits for mental health and substance use disorder services RL Garfield, JR Lave, JM Donohue Psychiatric services 61 (11), 1081-1086, 2010 | 123 | 2010 |
| Trends in use of antipsychotics in elderly patients with dementia: impact of national safety warnings A Gallini, S Andrieu, JM Donohue, N Oumouhou, M Lapeyre-Mestre, ... European Neuropsychopharmacology 24 (1), 95-104, 2014 | 121 | 2014 |
| Promotion of prescription drugs to consumers and providers, 2001–2010 R Kornfield, J Donohue, ER Berndt, GC Alexander PloS one 8 (3), e55504, 2013 | 121 | 2013 |
| The Effects Of The Coverage Gap On Drug Spending: A Closer Look At Medicare Part D: Beneficiaries who entered the “doughnut hole” decreased their monthly prescriptions by about … Y Zhang, JM Donohue, JP Newhouse, JR Lave Health Affairs 28 (Suppl1), w317-w325, 2009 | 120 | 2009 |
| Association between trajectories of buprenorphine treatment and emergency department and in‐patient utilization WH Lo‐Ciganic, WF Gellad, AJ Gordon, G Cochran, MA Zemaitis, ... Addiction 111 (5), 892-902, 2016 | 111 | 2016 |
| Using machine learning to examine medication adherence thresholds and risk of hospitalization WH Lo-Ciganic, JM Donohue, JM Thorpe, S Perera, CT Thorpe, ... Medical care 53 (8), 720-728, 2015 | 90 | 2015 |
